-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMIX BIOPHARMA ANNOUNCES 89% COMPLETE RESPONSE RATE AT INTERIM UPDATE ACROSS ALL NEXICART-2 PATIENTS, WITH MRD-NEGATIVITY INDICATING POTENTIAL TO REACH UP TO 98% COMPLETE RESPONSE RATE, SUPPORTING POTENTIAL BEST-IN-CLASS THERAPY FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

Reuters·09/29/2026 11:02:11